Comparison of the Effectiveness of Nerve Hydrodissection With Saline Injection of 5% Dextrose in Carpal Tunnel Syndrome.

Evaluation of Pain, Hand Function, Electrophysiological and Ultrasonographic Effects When Comparing 5% Dextrose Saline Injection Via Nerve Hydrodissection Under Ultrasound Guidance in Mild to Moderate Carpal Tunnel Syndrome.

Comparison of the effectiveness of nerve hydrodissection with saline injection of 5% dextrose in carpal tunnel syndrome.

Study Overview

• Status: Active, not recruiting
• Conditions: Conditions
• Intervention / Treatment: Drug: Nerve Hydrodissection with 5% Dextrose

Detailed Description

Evaluation of pain, hand function, electrophysiological and ultrasonographic effects when comparing 5% dextrose saline injection via nerve hydrodissection under ultrasound guidance in mild to moderate carpal tunnel syndrome.

• Study Type: Interventional
• Enrollment (Actual): 96
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Turkey (Türkiye)
  • Antalya, Turkey (Türkiye)
    • Antalya Eğitim Araştırma Hastanesi

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adults aged 18-80 years
• Clinical and electrophysiological diagnosis of mild to moderate carpal tunnel syndrome
• Symptom duration of at least 3 months
• Both male and female participants
• Patients who have not responded adequately to conservative treatment
• Patients who do not wish to undergo surgical treatment
• Ability to provide informed consent

Exclusion Criteria:

• Severe or very severe carpal tunnel syndrome based on EMG findings
• Previous injection therapy for carpal tunnel syndrome
• Prior wrist or carpal tunnel surgery
• Polyneuropathy or other peripheral neuropathies
• Cervical radiculopathy or proximal median nerve entrapment
• Brachial plexopathy or thoracic outlet syndrome
• Pregnancy
• Malignancy
• Local or systemic infection
• Cognitive impairment affecting cooperation
• Systemic diseases affecting the median nerve (e.g., uncontrolled diabetes mellitus, thyroid disorders)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: 5% dextrose group; Ultrasound-guided median nerve hydrodissection with 5% dextrose	Drug: Nerve Hydrodissection with 5% Dextrose; Injection therapy; Other Names: Saline Injection (Placebo / Sham), Splint group
Sham Comparator: Saline group; Sham ultrasound-guided perineural injection with normal saline	Drug: Nerve Hydrodissection with 5% Dextrose; Injection therapy; Other Names: Saline Injection (Placebo / Sham), Splint group
Sham Comparator: Splint group; Patients use only a wrist splint without injection therapy	Drug: Nerve Hydrodissection with 5% Dextrose; Injection therapy; Other Names: Saline Injection (Placebo / Sham), Splint group

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in pain intensity measured by Visual Analog Scale (VAS)	The primary outcome is the change in pain intensity assessed by the Visual Analog Scale (VAS, 0-10). The difference between baseline and follow-up scores will be analyzed.	Baseline to 8 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Qucik DASH score	Assessed using symptom severity and functional status scales	Baseline to 8 month
Change in median nerve cross-sectional area	Measured at the carpal tunnel inlet using ultrasonography	Baseline to 8 month
hange in nerve conduction study parameters	Distal motor latency and sensory conduction velocity of the median nerve	Baseline to 8 month
Change in hand grip strength	Strength of the arm	Baseline to 8 month

Collaborators and Investigators

• Sponsor: Antalya Training and Research Hospital

Study record dates

Study Major Dates

• Study Start (Actual): January 8, 2026
• Primary Completion (Estimated): July 10, 2026
• Study Completion (Estimated): July 10, 2026

Study Registration Dates

• First Submitted: March 30, 2026
• First Submitted That Met QC Criteria: April 6, 2026
• First Posted (Actual): April 13, 2026

Study Record Updates

• Last Update Posted (Actual): April 13, 2026
• Last Update Submitted That Met QC Criteria: April 6, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Pathological Conditions, Signs and Symptoms; Disease; Carbohydrates; Inorganic Chemicals; Chlorine Compounds; Sugars; Sodium Compounds; Hexoses; Monosaccharides; Chlorides; Hydrochloric Acid; salicylhydroxamic acid; Glucose; Sodium Chloride
• Other Study ID Numbers: 2026528

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No